Skip to main content
. Author manuscript; available in PMC: 2019 Apr 15.
Published in final edited form as: Cancer. 2018 Jan 16;124(8):1798–1807. doi: 10.1002/cncr.31230

Table 3.

Adjusted hazard ratios and 95% confidence intervals for breast cancer, cardiovascular disease, and other cause mortality by the presence of cardiometabolicrisk factors at WHI baseline enrollment

Breast Cancer Mortality CVD Mortality Other Cause Mortality
Deaths HR 95 % CI Deaths HR 95 % CI Deaths HR 95% CI
Unadjusted

High Waist Circumference

  No 339 Ref 234 Ref 575 Ref

  Yes 279 1.23 1.05–1.44 224 1.46 1.22–1.76 528 1.41 1.25–1.59

History of High Cholesterol

  No 496 Ref 342 Ref 883 Ref

  Yes 75 1.01 0.79–1.28 90 1.77 1.40–2.23 149 1.14 0.96–1.36

History of Diabetes

  No 589 Ref 419 Ref 1,015 Ref

  Yes 30 1.04 0.72–1.50 39 1.92 1.38–2.66 88 1.80 1.44–2.23

High Blood Pressure

  No 360 Ref 178 Ref 559 Ref

  Yes 259 1.09 0.93–1.27 279 2.40 1.99–2.90 543 1.49 1.33–1.68

Cardiometabolic Abnormalities

  None 181 Ref 68 Ref 254 Ref

  1 – 2 Abnormalities 357 1.18 0.99–1.41 313 2.83 2.17–3.67 693 1.68 1.45–1.94

  3 – 4 Abnormalities 32 1.23 0.84–1.79 48 5.13 3.54–7.42 84 2.42 1.89–3.09

  p-trend 0.068 <.001 <.001

Adjusted*

High Waist Circumference

  No 339 Ref 234 Ref 575 Ref

  Yes 279 1.19 0.93–1.52 224 1.28 1.05–1.57 528 1.32 1.16–1.49

History of High Cholesterol

  No 496 Ref 342 Ref 883 Ref

  Yes 75 0.96 0.75–1.22 90 1.30 1.02–1.65 149 0.94 0.79–1.12

History of Diabetes

  No 589 Ref 419 Ref 1,015 Ref

  Yes 30 0.81 0.54–1.21 39 1.52 1.07–2.16 88 1.58 1.25–1.98

High Blood Pressure

  No 360 Ref 178 Ref 559 Ref

  Yes 259 0.95 0.80–1.13 279 1.67 1.37–2.04 543 1.15 1.02–1.31

Cardiometabolic Abnormalities

None 181 Ref 68 Ref 254 Ref

  1 – 2 Abnormalities 357 1.05 0.86–1.29 313 2.06 1.58–2.69 693 1.39 1.20–1.61

  3 – 4 Abnormalities 32 0.97 0.65–1.46 48 3.29 2.25–4.82 84 1.90 1.49–2.44

  p-trend 0.857 <.001 <.001

Models adjusted for age group, WHI trial (OS vs CT), and covariates that modified the HR for 3–4 cardiometabolic abnormalities by 5% or more. In addition, individual cardiometabolic abnormalities were adjusted for one another. For breast cancer mortality, models adjusted for age group, WHI trial, race, alcohol intake, episodes of moderate to strenuous physical activity, and BMI. For CVD mortality, models adjusted for age group, WHI trial, alcohol intake, episodes of moderate to strenuous physical activity, and hormone therapy use. For other cause mortality, models adjusted for age group and WHI trial.